You are viewing the site in preview mode

Skip to main content

Volume 6 Supplement 2

Current and new antitumor necrosis factor agents in perspective

Reviews

Edited by Peter E Lipsky and Ravinder N Maini

Supported by an educational grant from Centocor, Inc.

  4. Tumor necrosis factor (TNF) antagonists are biologic response modifiers that have significantly improved functional outcomes in patients with rheumatoid arthritis (RA). RA is a progressive disease in which str...

    Authors: David Yocum
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S24
    Content type: Review Published on:

  6. Ankylosing spondylitis (AS) is a member of the family of spondyloarthropathies, which are inflammatory arthritides largely involving the axial skeleton and commonly accompanied by peripheral arthritis. Genetic...

    Authors: Paul M Peloso and Jürgen Braun
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S36
    Content type: Review Published on:

  7. Tumor necrosis factor (TNF) antagonists have dramatically improved the outcomes of rheumatoid arthritis (RA). Three agents currently available in the USA – infliximab, etanercept, and adalimumab – have been de...

    Authors: Sergio Schwartzman, Roy Fleischmann and G James Morgan Jr
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S3
    Content type: Review Published on:

  8. Psoriatic arthritis (PsA) is a seronegative spondyloarthropathy that commonly appears after the onset of the characteristic cutaneous lesions. This complication affects about 40% of patients with moderate to s...

    Authors: Alice B Gottlieb and Christian E Antoni
    Citation: Arthritis Research & Therapy 2004 6(Suppl 2):S31
    Content type: Review Published on:
  • Logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 4.4
    5-year Journal Impact Factor: 4.9
    Source Normalized Impact per Paper (SNIP): 1.294
    SCImago Journal Rank (SJR): 1.518

    Speed 2024
    Submission to first editorial decision (median days): 11
    Submission to acceptance (median days): 118

    Usage 2024
    Downloads: 3,978,337
    Altmetric mentions: 1,452

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us